Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Bristol-Myers Squibb Co shares valued at $38,930 were sold by Holzer Phil M on Nov 04 ’24. At $55.62 per share, Holzer Phil M sold 700 shares. The insider’s holdings dropped to 11,760 shares worth approximately $0.7 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Hirawat Samit purchased 1,830 shares, netting a total of over 100,055 in proceeds. Following the buying of shares at $54.67 each, the insider now holds 62,109 shares.
Before that, Holzer Phil M had added 700 shares to its account. In a trade valued at $38,930, the Officer bought Bristol-Myers Squibb Co shares for $55.62 each.
As published in their initiating research note from Wolfe Research on November 15, 2024, Bristol-Myers Squibb Co [BMY] has been a Peer perform. Analysts at Daiwa Securities upgraded the stock from ‘”a Neutral”‘ to ‘”an Outperform”‘ outlook in a report released in mid November. As of November 12, 2024, Leerink Partners has increased its “Market perform” rating to a “an Outperform” for BMY. Earlier on October 25, 2024, Citigroup downgraded its rating. Their new recommendation was “a Neutral” for BMY stock which previously was a “a Buy”.
Analyzing BMY Stock Performance
During the last five days, there has been a surge of approximately 2.40%. Over the course of the year, Bristol-Myers Squibb Co shares have jumped approximately 15.51%. Shares of the company reached a 52-week high of $61.08 on 11/11/24 and a 52-week low of $39.35 on 07/05/24. A 50-day SMA is recorded $54.21, while a 200-day SMA reached $48.68. Nevertheless, trading volume fell to 6.58 million shares from 7.43 million shares the previous day.
Support And Resistance Levels for Bristol-Myers Squibb Co (BMY)
According to the 24-hour chart, there is a support level at 58.86, which, if violated, would cause prices to drop to 58.46. In the upper region, resistance lies at 59.59. The next price resistance is at 59.91. RSI (Relative Strength Index) is 63.74 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.87, which suggests the price will decrease in the coming days. Percent R is at 25.46%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
